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Sciences, The Florida State University, College of Medicine, Tallahassee, FloridaABSTRACT Three troponin T (TnT) mutants that cause hypertrophic, restrictive, and dilated cardiomyopathy (I79N,DE96, and
DK210, respectively), were examined using the thin-filament extraction/reconstitution technique. Effects of Ca2þ, ATP, phos-
phate, and ADP concentrations on force and its transients were studied at 25C. Maximal Ca2þ tension (THC) and Ca
2þ-activat-
able tension (Tact), respectively, were similar among I79N, DE96, andWT, whereasDK210 led to a significantly lower THC (~20%
less) and Tact (~25% less) than did WT. In pCa solution containing 8 mM Pi and ionic strength adjusted to 200 mM, the Ca
2þ
sensitivity (pCa50) of I79N (5.63 5 0.02) and DE96 (5.60 5 0.03) was significantly greater than that of WT (5.45 5 0.04),
but the pCa50 of DK210 (5.545 0.04) remained similar to that of WT. Five equilibrium constants were deduced using sinusoidal
analysis. All three mutants showed significantly lower K0 (ADP association constant) and larger K4 (equilibrium constant of force
generation step) relative to the corresponding values for WT. I79N and DK210 were associated with a K2 (equilibrium constant of
cross-bridge detachment step) significantly lower than that of DE96 and WT. These results demonstrated that at pCa 4.66, the
force/cross-bridge is ~18% less in I79N and ~41% less in DK210 than that in WT. These results indicate that the molecular path-
ogenesis of the cardiac TnT mutation-related cardiomyopathies is different for each mutation.INTRODUCTIONCardiac troponin T (cTnT) is the tropomyosin (Tm)-binding
subunit of the troponin (Tn) complex, but cTnT has many
more complex functions than simply tethering Tm to
Tn (1). The latter also include the Ca2þ-binding subunit
(cTnC) and the subunit that inhibits the actomyosin (AM)
interaction (cTnI) (2–4). In addition to regulating the AM
interaction via Tm, cTnT is now known to interact with
actin, whereby it may affect actin-Tm binding (5). cTnT
has also been reported to play a critical role in sarcomere as-
sembly (6). The phosphorylation of cTnT is known to affect
normal function of cardiac muscle fibers (myocardium) (7).
So far, 49 cTnT mutations have been identified and related
to various forms of cardiomyopathy: familial hypertrophic
cardiomyopathy (HCM), dilated cardiomyopathy (DCM),
and restrictive cardiomyopathy (RCM) (8). This diversity
in disease implies that cTnT is involved in multiple physio-
logical processes. Notably, mutations in cTnT account for
15% of all HCM cases (8), and HCM patients carrying
mutations in cTnT have a much higher incidence of sudden
cardiac death (SCD) at an early age than do HCM patients
who carry mutations in other sarcomeric proteins (8,9).
I79 lies near a putative Tm-binding region of cTnT (10).
A patient study indicated that the I79N lesion causes a high
rate of SCD in young adults and that the prognosis in these
cases is poor (11). However, the reported effects of I79N
have been conflicting, in the cases of both in vitro and
in vivo studies. For example, I79N was reported to increase
Ca2þ sensitivity (pCa50) in adult rats expressing an embry-Submitted November 26, 2012, and accepted for publication April 2, 2013.
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in an ATPase assay carried out with rat cTnT-I79N (13). An
in vitro motility assay showed that I79N increased the
sliding velocity (13). Transgenic mice harboring a human
cTnT-I79N mutation showed neither hypertrophy nor short-
ened survival (14). Skinned fibers from these transgenic
mice showed an increase in pCa50, a decrease in maximum
tension and ATPase activity, and an increase in the rates of
force activation and relaxation (14).
E96 is located within the Tm-binding region of cTnT
(10). Patients carrying the DE96 mutation feature both dia-
stolic and systolic dysfunction, and the prognosis is severe
(15). Fibers reconstituted with the DE96 mutant exhibited
an increased pCa50 and impaired muscle relaxation, but
the maximal force generated did not differ significantly
from that in fibers reconstituted with the WT protein (16).
K210 is located in a highly charged region in the IT arm,
which is a rigid coiled-coil structure in the Tn complex
where TnI and TnT bind, and which is a part of the core
domain of the Tn complex and is in close contact with a
highly charged region of cTnI (17). Two hydrogen bonds
(cTnT E214-cTnI R98 and cTnT R216-cTnI D105) have
been shown to stabilize the IT interaction (17). Patients
with the DK210 mutation manifest severe clinical disease,
including a significant incidence of early SCD (18). Func-
tional analysis has demonstrated that DK210 results in
decreases in pCa50, maximal ATPase activity, and force
generated by the affected cardiac fibers (19,20). However,
analysis of a transgenic mouse model of DK210 showed
that pCa50 was decreased but that the maximal force was
not decreased (21). A recent study also showed that
DK210 led to changes in the phosphorylation status ofhttp://dx.doi.org/10.1016/j.bpj.2013.04.001
1980 Bai et al.several sarcomeric proteins, including cMyBP-C, cTnT, and
cTnI, indicating that the consequences of the DK210 muta-
tion go far beyond the IT interaction (22).
The literature regarding Tn mutations and their roles in
disease and muscle regulation is extensive. Previous studies
have focused on measurement of three parameters: Ca2þ
sensitivity (pCa50), maximal force (THC), and force during
relaxation (TLC). Based on these analyses, it is believed
that the Tn mutations that cause hypertrophic and restrictive
cardiomyopathy lead to an increase in pCa50, whereas the
mutations that cause dilated cardiomyopathy lead to
decreased pCa50 (8). However, none of those studies evalu-
ated the cross-bridge kinetics, which affect the ability of
myosin to generate force and are hence essential in charac-
terizing early pathogenesis that leads to cardiomyopathy.
In this study, the thin-filament extraction/reconstitution
technique was used instead of the traditional Tn replacement
technique. The latter has been used extensively by investiga-
tors and shown to be a reliable technique for studying
Tn functions (7,23–25). Our thin-filament extraction/
reconstitution technique, although more invasive than the
Tn replacement technique, has been shown to fully restore
isometric tension, Ca2þ sensitivity, cooperativity, apparent
rate constants, and kinetic constants of the elementary steps
of the cross-bridge cycle (26–28) (see Supporting Material
for a detailed comparison of these two methods). We have
further evaluated the reconstituted fibers using SDS-PAGE
(29) and electron microscopy (26), with satisfactory results.
After thin-filament reconstitution, the effects of three car-
diomyopathy-linked cTnT mutants on isometric tension,
stiffness, and cross-bridge kinetics were studied using sinu-
soidal analysis.
Our results are as follows: 1), all three cTnT mutants
caused significantly accelerated ADP dissociation from the
myosin head; 2), I79N and DK210 caused a decrease in
the cross-bridge detachment rate and an increase in the num-
ber of actively cycling cross-bridges; 3), I79N and DE96
caused a significant increase in pCa50 without altering the
maximum force, but DK210 caused a decrease in maximum
force with unchanged pCa50. These results are discussed in
the context of the early pathogenesis of each mutation.MATERIALS AND METHODS
Experimental materials and the thin-filament
extraction/reconstitution technique
Small bundles (length ~10 mm, diameter ~1–2 mm) of bovine trabecular
muscles were dissected from right ventricles and chemically skinned
(28). On the day of experiments they were further split into thin bundles
(length ~2 mm, diameter 90–110 mm), mounted in the experimental
apparatus, and stretched to a sarcomere length of ~2.1 mm. Thin-filament
extraction and reconstitution were performed as described previously
(30), as originally developed in the Ishiwata laboratory (27) and refined
in the Kawai laboratory (26) (Fig. S1 in the Supporting Material). The
protein concentrations used were 1.5 mg/ml actin, 0.33 mg/ml Tm, and
0.78 mg/ml Tn (28).Biophysical Journal 104(9) 1979–1988Proteins
Rabbit skeletal-muscle G-actin was purified as described elsewhere (31).
Bovine cardiac Tm and Tn were purified from fresh cow hearts, as
described elsewhere (32). Both proteins were purified in the Kawai labora-
tory. Human WT and mutant cTnT, human cTnI, and human cTnC were
expressed as recombinant proteins in E. coli and purified in the Potter
laboratory. The WT and mutant cTn complex proteins used for reconstitu-
tion were 97–99% pure (16).Experimental solutions
Solutions were prepared as described (30). In the case of pCa solution, two
sets of solutions were used, one at 8 mM Pi and 200 mM ionic strength (IS)
(30) and the other at 0 mM Pi and 150 mM IS (33). I79N and DE96 were
studied only in the 8 mM Pi pCa solutions, whereas DK210 was studied in
both pCa solutions.Tension normalization
All tension values were normalized to Ta, the tension of actin-filament
reconstituted fibers in the absence of Tm and Tn, and in standard activating
solution (8 mM Pi and IS 200 mM) (30). This solution closely mimics
the physiological environment in cardiomyocytes, in which [Pi] during
contraction was reported to be ~6 mM (34) and IS ~215 mM (35). The
reason for using Ta instead of the absolute tension in Pascals is that this
minimizes the scatter of data stemming from error in estimating the
cross-sectional area of the fibers. In this study, Ta averaged to 13.8 5
0.7 kPa (N ¼ 63). Ta increased 1.5-fold on reconstitution with Tm and
Tn (26–28), twofold when Pi was deleted from the activating saline
(30,36), and 1.2-fold when IS was reduced from 200 mM to 150 mM
(37,38), as has often been done in experiments performed by other investi-
gators. Multiplication of these values by the Ta results in a value of 50 kPa
(13.8 kPa 1.5 2  1.2), consistent with the range of values reported for
rat cardiac muscle fibers (39–75 kPa) (39,40).pCa-tension study
The pCa-tension study was performed as described previously (41) across a
pCa range of 8.0–4.66. The tension and stiffness at pCa 8.0 (low Ca2þ) are
termed TLC and YLC, respectively; the stiffness is defined as YN (42), but
the N symbol is dropped for simplicity. The tension and stiffness at pCa
4.66 (high Ca2þ) are referred to as THC and YHC, respectively. The baseline
tension was measured in super-relaxing solution (30) at 0C, in the presence
of 6 mM EGTA, 5 mM MgATP, and 40 mM BDM; neither tension nor
cross-bridge cycling are significant under this condition. The pCa-tension
relationship was fitted to the Hill equation:
Tension ¼ Tact
1þ

Ca50
½Ca2þ
nH þ TLC; (1)
where pCa¼ –log10[Ca2þ], Tact is the Ca2þ-activatable tension, and Ca50 is
the apparent Ca2þ dissociation constant, which represents the Ca2þ concen-
tration at half tension. pCa50 (–log10Ca50) represents Ca
2þ sensitivity, and
nH (the Hill factor) represents cooperativity. THC¼ Tactþ TLC is the tension
at high [Ca2þ]. pCa-tension curves were individually fitted to Eq. 1, and the
fitted parameters were averaged. All experiments were carried out at 25C.Sinusoidal analysis
The elementary steps of the six-stage cross-bridge cycle (Fig. S2) were
studied using sinusoidal analysis as described previously (42,43).
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pCa-tension studies
To demonstrate the integrity of our preparations and the
effectiveness of our method, we first studied the pCa-tension
relationship in native bovine cardiac muscle fibers (Fig. 1,
dashed curves with open circles) and thin filaments reconsti-
tuted with actin, Tm, and the Tn complex purified from
bovine ventricle (Fig. 1, curves with solid squares). Notably,
the two plots are almost identical, and when the data were
fitted to Eq. 1, we obtained pCa50 ¼ 5.69 5 0.01 and
nH ¼ 3.22 5 0.18 (mean 5 SE, N ¼ 14) for native fibers,
and pCa50¼ 5.685 0.02 and nH¼ 2.715 0.23 (N¼ 9) for
thin-filament-reconstituted fibers. The values for these pa-
rameters are not significantly different. The reproducibility
of tension in thin-filament-reconstituted fibers was 104 5
3% (N ¼ 38), which is not statistically different from 100%.
To determine the effects of cardiomyopathy-related
cTnT mutants on TLC, THC, pCa50, and nH, we studied the
pCa-tension relationship of the thin-filament-reconstituted
myocardium. Fig. 2 shows pCa-tension plots for mutant
and WT cTnTs. The results of the experiments, which
were carried out at 8 mM Pi, are plotted in Fig. 3. Tact of
I79N (Fig. 2 A) appears larger than that of WT, but the
difference is insignificant. Tact of DE96 (Fig. 2 B) is nearly
identical to that of WT, but pCa50 of DE96 appears slightly
larger than that of WT. Tact of DK210 (Fig. 2 C) appears to
be significantly smaller than that of WT.FIGURE 1 pCa-tension plot comparing native cardiac muscle fibers
(dashed curves with open circles) and fibers reconstituted with bovine car-
diac actin, Tm, and Tn (curves with solid squares). Normalized tension is
plotted against pCa. The symbols represent the data points and the curves
represent the best fit to Eq. 1. Error bars represent the mean 5 SE, but
most are smaller than the symbol size. The pCa50 value was identical
between native fibers (5.69 5 0.01, N¼14) and fibers reconstituted with
bovine cardiac actin, Tm, and Tn (5.685 0.02, N¼9). Although the coop-
erativity of actin, Tm, and Tn-reconstituted myocardium (2.71 5 0.23,
N¼9) was slightly less than that of native fibers (3.22 5 0.18, N¼14),
this difference was not statistically significant.The results for pCa-tension were fitted to Eq. 1; the
average values of parameters are listed in Table S1 and
plotted in Fig. 3. None of the three cTnT mutants showed
significant changes in TLC compared to WT (Fig. 3 A).
With respect to maximal force, THC values for I79N
(1.82 5 0.13 Ta) and DE96 (1.66 5 0.14 Ta) were similar
to that of WT (1.68 5 0.13 Ta), but THC for DK210
(1.33 5 0.12 Ta) was significantly lower than that of WT.
Tact followed the general pattern observed for THC. The
YLCs of DE96 and DK210 were similar to that of WT, but
YLC of I79N was significantly less than that of WT
(Fig. 3 B). YHC was similar in all genotypes studied, but
Yact of I79N was significantly larger than that of the others.
Cooperativity was calculated by averaging individual nH
values (Fig. 3 C). Only I79N (2.535 0.22) showed signif-
icantly increased nH compared to that of WT (1.715 0.18).
The pCa50 values for I79N (5.635 0.02, N¼ 16) and DE96
(5.60 5 0.03) were significantly larger than that of WT
(5.45 5 0.04), indicating increased Ca2þ sensitivity,
whereas that of DK210 (5.545 0.04) did not differ signif-
icantly from that of WT (Fig. 3 D).
Although our results demonstrate that pCa50 is not sig-
nificantly different between DK210 and WT, previous
reports have shown a decrease in pCa50 with this mutant
(19,20,44). One reason for this apparent disagreement is
that the solutions used were different. Whereas we used
solutions at 8 mM Pi and IS 200 mM, previous investigators
used solutions without added Pi and IS at 150 mM. For this
reason, we also studied DK210 and WT in solution at 0 mM
Pi and IS 150 mM (see Fig. 2 D). When Fig. 2, C and D, are
compared, the decreases in [Pi] (from 8 mM to 0 mM) and
IS (from 200 mM to 150 mM) shifted the pCa-tension
curves to the left (increase in pCa50), decreased the slope
(reduced cooperativity), and increased THC significantly
and as reported previously (45). When compared at 0 Pi
and IS 150 mM, DK210 caused a significant decrease in
THC (2.74 5 0.27 Ta, N ¼ 6) compared to that in WT
(3.62 5 0.33 Ta, N ¼ 6). The pCa50 of DK210 (5.65 5
0.06, N ¼ 6) was significantly less than that of WT
(5.89 5 0.03, N ¼ 6), consistent with findings from
previous studies (19,21,44). The cooperativity of DK210
(1.29 5 0.21, N ¼ 6) was significantly less than that of
WT (1.90 5 0.15, N ¼ 6).Sinusoidal analysis and cross-bridge kinetics
Sinusoidal analysis was performed to characterize the
elementary steps of the cross-bridge cycle (Fig. S2) in the
reconstituted myocardium (26,42). The apparent rate con-
stants 2pb and 2pc were measured as functions of [Pi]
and [MgATP] (Fig. 4). All mutants exhibited some differ-
ences in 2pc relative to the WT value (Fig. 4, A–C), but
these differences were small. I79N and DE96 caused a large
increase in 2pb compared to that observed in the WT and
DK210 preparations (Fig. 4, D–F). The rate and associationBiophysical Journal 104(9) 1979–1988
FIGURE 2 pCa-tension plots comparingWTand three mutant forms of TnT. The mean5 SE values for 12–20 experiments are shown. (A–C) pCa-tension
curves for the mutants andWTat IS 200 mM and 8 mM Pi. (D) Curves forDK210 andWTat IS 150 mM and 0 mM Pi. Tension is normalized to Ta¼ 13.795
0.73 kPa (n ¼ 63).
1982 Bai et al.constants of the elementary steps as defined in the cross-
bridge model (Fig. S2) are collectively referred to as kinetic
constants and were deduced by fitting the dependence of
apparent rate constants on ligand concentrations to Eqs.FIGURE 3 Results of pCa-tension studies. (A) Isometric tension: THC, Tact, a
Tension and stiffness were normalized to Ta. *p < 0.05.
Biophysical Journal 104(9) 1979–1988S2–S4. The kinetic constants for the mutant and WT pro-
teins are compared in Fig. 5. All kinetic constants changed
to some extent in the mutants, but the only changes that were
significant (p < 0.05) were as follows. All three TnTnd TLC are as defined in Eq. 1. (B) Stiffness. (C) Cooperativity. (D) pCa50.
FIGURE 4 Apparent rate constants. (A–C) 2pc is plotted against [MgATP]. (D–F) 2pb is plotted against [Pi]. Mean 5 SE values are shown for 9–19
experiments. Solid curves are the best fit of the data to Eqs. S2–S4 (69).
Molecular Pathogenesis of cTnT Mutants 1983mutants showed a significant decrease in K0, the ADP asso-
ciation constant (I79N, 30 5 2 mM1; DE96, 35 5
4 mM1; DK210, 275 3 mM1), and a significant increase
in K4, the force-generation step (I79N, 0.705 0.06; DE96,
0.28 5 0.01; DK210, 0.85 5 0.12) compared to WT
(K0 ¼ 47 5 1 mM1 and K4 ¼ 0.21 5 0.03). The I79N
and DK210 exhibited a significant decrease in K2, the
cross-bridge detachment step (I79N, 0.80 5 0.11; DE96,FIGURE 5 Comparison of the kinetic constants.0.85 5 0.13) compared to that of DE96 (1.74 5 0.24)
and WT (1.48 5 0.26). K1, the ATP association constant,
remained similar among the mutant and WT preparations,
as did K5 (Pi association constant). k2, the forward rate
constant of the cross-bridge detachment step, decreased
significantly in I79N (14.4 5 1.8 s1) and DK210
(15.9 5 1.5s1) compared to WT (21.4 5 0. 3s1),
but increased significantly in DE96 (27.0 5 3.8 s1). k4,(A) Rate constants. (B) Equilibrium constants.
Biophysical Journal 104(9) 1979–1988
1984 Bai et al.the rate constant of the force-generation step, increased
significantly in all mutants (I79N,13.7 5 1.2 S1; DE96,
17.6 5 1.1S1; DK210, 44.8 5 5.9S1) compared to WT
(7.6 5 1.8S1).Cross-bridge distribution and force/cross-bridge
There are two possible explanations for the change observed
in isometric tension (Fig. 3 A): a change in the number of
force-generating cross-bridges, or a change in the force
generated per cross-bridge. For this reason, the distribution
of cross-bridges in each state under standard activating
conditions (30) was calculated using the observed kinetic
constants as described previously (46); the results are shown
in Fig. 6. Also included is the probability of a strongly
attached (force-generating) state (Att), where Att ¼
AMD þ AM þ AM*S þ AM*DP þ AM*D ¼ 1  Det.
There were no significant effects of mutations in the three
left-side states (AMD, AM, AM*S), and significant changes
were limited to three right-side states (Det, AM*DP,
AM*D). I79N and DK210 caused significant decreases in
the detached state (Det, I79N, 24.9 5 1.3%; DK210,
23.1 5 1.4%) compared to the WT (43.4 5 2.3%), and
these were countered by significant increases of the
AM*DP state (I79N, 17.4 5 0.9%; DK210, 19.7 5
1.6%) and the AM*D state (I79N, 19.8 5 2.9%; DK210,
22.4 5 1.8%) compared to the corresponding states for
WT (AM*DP, 9.1 5 1.1%; AM*D, 8.7 5 1.2%). These
changes resulted in significant increases in the Att state.
I79N and DK210 showed an ~33% increase in the number
of force-generating cross-bridges (I79N, 75.1 5 1.3%;
DK210, 76.8 5 1.4%) relative to the number for WTFIGURE 6 Cross-bridge distribution. The kinetic constants were used to
calculate the cross-bridge distribution over six states under the standard
activating condition (5 mM MgATP, 8 mM Pi, 0.02 mM MgADP, and
pCa 4.66). Att indicates the sum of all strongly attached (force-generating)
cross-bridges. The distribution was calculated individually and averaged for
9–13 fibers.
Biophysical Journal 104(9) 1979–1988(56.6 5 2.3%). DE96 showed a cross-bridge distribution
similar to that in WT. These results demonstrate that
at pCa 4.66, the THC/cross-bridge (THC/(Att)) in I79N
is 2.4 5 0.2 Ta and ~18% less than that of WT (3.0 5
0.3 Ta), and THC/(Att) in DK210 it is 1.7 5 0.1 Ta and
~41% less than that of WT, but that THC/Xatt in DE96 is
2.9 5 0.3 Ta and similar to that of WT.DISCUSSION
As a key component of the cardiac excitation-contraction
coupling, TnT is responsible for holding Tm in its inhibi-
tory position in the absence of Ca2þ and thereby for block-
ing the AM interaction (47). TnT interacts with Tm in the
presence of Ca2þ, and moves Tm into the closed position,
which permits some cross-bridges to attach (1). The
attached cross-bridges further shift Tm to the open position,
permitting more cross-bridges to be strongly attached to
actin (26,32,48–51). E96 of cTnT is located within the
Tm-binding region, and I79 is located next to this region
(10). A mutation in TnT may shift the Tm position and
affect the otherwise strong interaction between actin and
myosin. Our earlier results demonstrated that the pres-
ence/absence of Tm (26), as well as point mutations of
Tm (30,45), modify the force/cross-bridge and cross-bridge
kinetics.
Earlier studies have demonstrated that in the context of
cardiomyopathy-causing Tm mutants, TLC is abnormal. In
HCM this value is increased (30), and in DCM (45) it is
decreased. Because of these findings, we focused on TLC,
assessing whether the same trend is observed with the
TnT mutants. However, none of the three cTnT mutants
exhibited abnormal TLC (Fig. 3 A) despite the differences
in phenotype with which they are associated. These observa-
tions imply that the blocked state of Tm is not affected in the
three cTnT mutants.
As shown by patient studies (11,15,18), the three cTnT
mutants lead to three different phenotypes and are associ-
ated with a prognosis more severe than that for disease
caused by mutations in other sarcomeric proteins. All three
cTnT mutants caused a significant increase in dissociation
of ADP from the myosin head (decreased K0, Fig. 5 B),
which suggests that the shortening velocity is faster. A pre-
vious study reported a doubling of the shortening velocity in
I79N (52), but the shortening velocity has not been
measured in DE96 and DK210. The increases in pCa50 in
I79N and DE96 (Table S1) are smaller than those reported
for Tm mutants (30), whose consequences are not as serious
as those reported for TnT mutants. Therefore, the poor prog-
nosis for patients harboring these mutations may result from
the combination of a change in pCa50 and alterations in
cross-bridges kinetics. The elementary steps of the cross-
bridge cycle are severely disturbed by these mutations
(Table S1 and Fig. 5). Our investigation demonstrates that
cTnT has far more influence on disease pathogenesis than
Molecular Pathogenesis of cTnT Mutants 1985merely regulating the AM interaction. Indeed, cTnT has
been shown to alter the posttranslational modification of
other sarcomeric proteins (22). Therefore, cTnT carries
more functions than a regulatory protein, which may help
to explain the poor prognosis of human patients carrying
cTnT mutations.
One of the controversies regarding the study of
cTnT mutations is that the values obtained for maxi-
mal force have been highly variable. Moreover, the
results obtained from Tn-reconstitution assays for HCM
mutations have often been inconsistent with those from
transgenic animals (14,16,53–56). Our earlier study
showed that tension recovery can be affected by the
solution systems used by different researchers (45). In
the case of transgenic animals, posttranslational modifica-
tions and isoform switching of the contractile proteins
may influence outcomes (22,57,58). Since the maximal
force varies among preparations (16,52,59,60), pCa50
should be considered a fingerprint that identifies those Tn
mutations that affect regulation. The results we report
here are consistent with the established Ca2þ-sensitivity
paradigm.
One important feature of this study of cTnT is that it in-
vestigates how mutations within a single protein disrupt
cardiac function in ways that lead to three phenotypes.
Are these phenotypes caused by different compensatory
mechanisms, or initiated by different molecular mecha-
nisms as a result of a change in cTnT (61,62)? The fact
that each mutation produced different results indicates
that each mutation should be considered independently of
the others.I79N
I79N results in the HCM phenotype, and it is associated
with a significant decrease in the equilibrium constant of
the cross-bridge detachment step (Fig. 5 B), a 20% decrease
in force/cross-bridge (THC/Xatt), significant increases in
pCa50 (0.18 5 0.04 unit) (Fig. 3 D), cooperativity
(Fig. 3 C), and the force-generation rate (k4 and K4;
Fig. 5). An earlier study in transgenic mice showed that
I79N caused a decrease in maximal force and an increase
in pCa50 (14). Cardiac performance analysis showed an in-
crease in end-diastolic pressure and relaxation time, but no
evidence of diastolic dysfunction (63). In our study, the
maximal force remained similar to that in WT preparations
(comparable THC and Tact among I79N and WT; Fig. 3 A),
demonstrating that this mutation does not immediately
result in a decrease in contractility. This result is consistent
with the findings using skinned fibers (55). The decrease in
maximal force may be caused by secondary effects of the
mutation, such as changed phosphorylation levels, as
mentioned below for DK210. Our kinetic analysis further
revealed that I79N caused an increase in the number
of Att states (Fig. 6), compensating for the decreasedforce/cross-bridge and maintaining normal force. Thus, at
the molecular level, there may be a compensatory mecha-
nism that maintains normal overall force. The decrease in
force/cross-bridge indicates that the normally strong bind-
ing between actin and myosin is weakened in I79N. The
cross-bridge detachment rate (k2) is decreased in I79N,
which may appear inconsistent with an earlier observation
that the rate of relaxation (g) increased in the I79N trans-
genic mouse model (14). However, this difference is a
consequence of using different models; given that we used
a realistic six-state model and the earlier report was based
on a two-state model, g must be a composite of multiple
steps.DE96
DE96 results in the RCM phenotype, but it did not signifi-
cantly influence many of the parameters we have studied,
except for the ADP dissociation constant (a decrease
in K0), cross-bridge detachment rate (an increase in k2),
and the kinetic constants of the force-generation step
(increase in k4, k4, and K4) (Fig. 5). DE96 also increased
pCa50 by 0.15 5 0.05 units (Fig. 3 D) without changing
the maximal force or stiffness (Fig. 3, THC, Tact, YHC, and
Yact). These results are consistent with the hypothesis that
the charged residue E96 is involved in the activation pro-
cess. The typical abnormal diastolic filling pattern in
RCM patients may be related to the abnormal ventricular-
wall stiffness in the context of low Ca2þ, with neither
tension (TLC) nor stiffness (YLC) changing (Fig. 3, A and
B). Force/cross-bridge did not change in the context of
high Ca2þ. A previous study on skinned fibers showed
that DE96 caused a significant increase in residual unregu-
lated tension (16), but this was not observed in the study
presented here. The different solution conditions discussed
below may explain this difference.DK210
DK210 results in a DCM phenotype, causing significant
decreases in the cross-bridge detachment rate (Fig. 5. k2
and K2), significant increases in the force-generation rate
(Fig. 5, k4, k4, and K4), and significant increases in the
probability of Att (Fig. 6). However, neither TLC, pCa50,
nor cooperativity changed significantly (Fig. 3). Although
K210 lies far from the Tm binding region, its deletion
may affect the position of Tm in the open state (49), result-
ing in partial shielding of the AM interaction and leading to
a decrease in the maximal forces (Fig. 3 A, THC and Tact) and
force/cross-bridge. The decrease in the Ca2þ activatable
tension (Tact) may cause a systolic problem, which explains
the emergence of DCM, consistent with findings from pre-
vious pathogenesis studies (19,20).
Our observation that pCa50 was unchanged by DK210
(Figs. 2 C and 3 D) is at variance with the findings ofBiophysical Journal 104(9) 1979–1988
1986 Bai et al.previous studies that reported a decrease in pCa50
(20,21,44). There are two possible explanations for this
disagreement.
1. There is a difference in the pCa solutions used. Our
solutions contained 8 mM Pi and IS was adjusted to
200 mM, whereas other investigators (20,21,44) used
no added Pi and IS 150 mM. When we used the latter
solution, we observed a decrease in pCa50 similar to
that previously reported (Fig. 2 D). In rabbit psoas fibers,
elevating IS from 128 mM to 201 mM decreases pCa50
by ~0.35 units (64), and increasing [Pi] from 0 to
7.5 mM decreases pCa50 by 0.23 units (65). Similar
effects of [Pi] on pCa50 have also been reported in cardiac
fibers (36,66). Consequently, changes in IS and [Pi] will
lead to significant changes in the pCa50 value and other
parameters for both WT and mutant proteins. However,
this effect may be different in each mutation. For
example, removing Pi and lowering IS caused the pCa50
of WT to increase by 0.44 unit. In contrast, the pCa50 of
DK210 only increased by 0.11 unit under the same condi-
tion. This difference directly leads to our observation that
DK210 decreased the Ca2þ sensitivity at 0 mM Pi and IS
150 mM. A similar difference was also reported in our
recent article on DCM-causing Tm mutants E40K and
E54K (45): their pCa50 decreased compared to that of
WT in the 0 mM Pi and 150 mM IS solutions, whereas
pCa50 did not change in the 8 mM Pi, IS 200 mM solu-
tions. These Tm mutants introduced a large change in
charge that destabilizes Tm’s coiled-coil structure. Previ-
ous studies on skinned cardiac fibers that used similar
0 mM Pi and low-IS solutions reported an increased
Ca2þ sensitivity for I79N and DE96 mutants of TnT
(12,14,16), which qualitatively agrees with our findings.
We conclude, therefore, that removing Pi and lowering
IS caused similar changes in pCa50 among I79N, DE96,
and the WT. Thus, these two mutants showed similarly
increased pCa50 values in two sets of pCa solutions.
It has been reported that physiological conditions in
contracting cardiomyoctes include ~4.5 mM ATP,
~6 mM Pi (34,67), and IS ~215 mM (35). Based on the
above-described findings, we conclude that pCa50 does
not differ between DK210 and WT under physiological
conditions, but that significant differences arise at IS
150 mM and 0 mM Pi. Our solution system is a better
approximation of the physiological condition, which
may be essential to understanding the physiological
consequence of a mutation.
2. The decrease in pCa50 may not be the direct result of a
mutation, but rather a secondary consequence thereof.
A transgenic mouse study showed that in vivo, the
DK210 mutant was associated with changes in the phos-
phorylation levels of sarcomeric proteins, including
cMyPB-C, cTnT, and cTnI (22). A change in phosphor-
ylation level can have significant consequences for theBiophysical Journal 104(9) 1979–1988contractile/regulatory response of the affected myocar-
dium (57,58,68), including a change in the pCa50 value.
In our studies, the background material (bovine myocar-
dium) is the same, and with the exception of the TnT
mutants, the proteins used to reconstitute the thin fila-
ment are the same. Consequently, we observe direct
effects of the mutation in the absence of masking by
other posttranslational modifications. Thus, we suggest
that the change in pCa50 observed by others in the case
of DK210 may have been caused by changes in post-
translational modification(s) of sarcomeric proteins.
Therefore, we can state that getting at the primary cause
is essential to restoring normal function.CONCLUSION
We conclude that three cTnT mutants (I79N, DE96, and
DK210) lead to distinct molecular pathogenesis, specifically
with regard to the mechanisms underlying cross-bridge
kinetics and force generation. The different downstream
effects eventually lead to the differences in disease pheno-
type. Although we conclude that a reduced isometric tension
is part of the defect and contributes to the disease pheno-
type, alterations in kinetic constants of the cross-bridge
cycle contribute as well and are responsible for the distinc-
tions between the disease phenotypes.SUPPORTING MATERIAL
One table, three figures, and materials and methods are available at http://
www.biophysj.org/biophysj/supplemental/S0006-3495(13)00392-5.
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